BioNTech (BNTX)
(Delayed Data from NSDQ)
$87.25 USD
+2.40 (2.83%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $87.26 +0.01 (0.01%) 7:44 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BNTX 87.25 +2.40(2.83%)
Will BNTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNTX
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Other News for BNTX
J.P. Morgan Sticks to Their Sell Rating for BioNTech SE (BNTX)
BioNTech price target lowered by $3 at JPMorgan, here's why
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Maravai cut at Morgan Stanley; Pfizer/BioNTech headwinds cited
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows